반응식
Cl[C:2]1[N:3]=[N:4][C:5]([C:8]2[CH:13]=[CH:12][N:11]=[CH:10][CH:9]=2)=[CH:6][CH:7]=1.[N:14]1([CH:19]2[CH2:24][CH2:23][NH:22][CH2:21][CH2:20]2)[CH2:18][CH2:17][CH2:16][CH2:15]1>>[N:11]1[CH:12]=[CH:13][C:8]([C:5]2[N:4]=[N:3][C:2]([N:22]3[CH2:23][CH2:24][CH:19]([N:14]4[CH2:18][CH2:17][CH2:16][CH2:15]4)[CH2:20][CH2:21]3)=[CH:7][CH:6]=2)=[CH:9][CH:10]=1참가 물질
3
실험 절차
The title compound was prepared by a similar procedure to that described in Example 1, starting from 3-chloro-6-(pyridin-4-yl)-pyridazine and 4-(1-pyrrolidinyl)piperidine. 1H NMR (400 MHz, CDCl3) δ 8.69 (d, 2H), 7.90 (d, 2H), 7.67 (d, 1H), 7.01 (d, 1H), 4.47 (d, 2H), 3.12 (m, 2H), 2.67 (s, 4H), 2.40 (m, 1H), 2.07 (d, 2H), 1.83 (s, 4H), 1.67 (m, 2H).
출처 및 근거
- ORD 기록
- ord-30611b51b89645b3a9fe0ad77f13f813
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08846677B2
연결된 노트
불러오는 중…